Am J Transplant, Volume 17, Suppl 3 Archives - Page 181 of 181 - ATC Abstracts

2017 American Transplant Congress
Resumption of Standard Dose Immunosuppression Following Resolution of BK Viremia Does Not Lead to Viremia Recurrence.
K. Alquadan, A. Santos, M. Casey, T. Ozrazgat-Baslanti, S. Bozorgmehri, J. Gregg, K. Womer.
Medicine, Nephrology, University of Florida, Gainesville, FL
Introduction: Reduction of immunosuppression (IS) in response to BK viremia following kidney transplantation prevents the development of BK virus nephropathy, with no apparent increase in…
2017 American Transplant Congress
Clinical Evaluation of the Safety and Preliminary Efficacy of Continuous Infusion of Treprostinil to Prevent Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplant Recipients.
O. Almazroo,¹ M. Miah,¹ V. Pillai,¹ A. Humar,² A. Tevar,² C. Hughes,² A. AlKhafaji,³ A. Demetris,⁴ S. Dermont,² S. Fedorek,² H. Johnson,¹ R. Lopez,² R. Planinsic,² B. Sengupta,² I. Sethu,² M. Sturdevant,² S. Ziobert,¹ R. Venkataramanan.^1,2,4
¹Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA; ²Thomas Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA; ³Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA; ⁴Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA
Introduction:Liver transplantation is currently the only therapeutic option for patients with end stage liver diseases. Liver allografts undergo cold ischemic injury and warm reperfusion injury…
2017 American Transplant Congress
CTLA4-Ig Inhibits Effector CD8⁺ T Cell Function In Vivo and Rescues Ongoing Acute Allograft Rejection.
J. Young,¹ S. Khiew,¹ J. Yang,¹ M.-L. Alegre,² A. Chong.¹
¹Surgery, University of Chicago, Chicago, IL; ²Medicine, University of Chicago, Chicago, IL
CLTA4-Ig is clinically approved for preventing rejection in kidney transplant recipients but current data suggest that it is less effective for memory T cells, and…
2017 American Transplant Congress
A New Methodology for Measuring and Monitoring Equity in Access to Deceased Donor Kidney Transplants.
D. Stewart, A. Wilk, W. Cherikh, A. Harper, R. Urban, D. Klassen, E. Edwards.
United Network for Organ Sharing, Richmond, VA
Background: The OPTN monitors progress on increasing the number of transplants, improving patient outcomes, and other goals. However, a well-established methodology for assessing system performance…
2017 American Transplant Congress
The Natural History of Kidney Rejection: How Do Molecular Disease States Change Over Time in Patients with Repeat Indication Biopsies?
J. Reeve, P. Halloran.
University of Alberta, Edmonton, AB, Canada
Molecular phenotypes are highly reproducible, but how do they evolve over time? In an unsupervised microarray analysis, 1208 kidney transplant biopsies were assigned to one…
2017 American Transplant Congress
The Degree of NK Cell Activation Determines the Ability of Donor-Specific Antibodies to Mediate Acute vs. Chronic Rejection of Kidney Allografts.
T. Yagisawa,^1,2 T. Tanaka,¹ N. Dvorina,¹ A. Valujskikh,¹ W. Baldwin 3rd,¹ R. Fairchild.¹
¹Immunology and Glickman Urological Institute, Cleveland Clinic, Cleveland, OH; ²Urology, Tokyo Women's Medical University, Tokyo, Japan
While the incidence of antibody-mediated kidney graft rejection has increased, the key cellular and molecular participants underlying this graft injury remain unclear. We have previously…